Search clinical trials for: Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)

Total 429 results

Tata Memorial Centre

Recruiting

Radiation Therapy in Unresectable Gall Bladder Cancer (RUGB)

Gall Bladder Cancer

India
Changhai Hospital

Recruiting

Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 (BRPCNCC-1)

Pancreatic Cancer

China
Hutchmed

Recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Fudan University

Recruiting

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

Breast Cancer

China
CHA University
Dong-A Pharmaceutical

Recruiting

Biomarker Discovery in Patients With Advanced Biliary Tract Cancer

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of
Jun Guo

Not yet recruiting

A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma

Urothelial Carcinoma

China
Taipei Veterans General Hospital, Taiwan

Completed

Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)

Non-small-cell Lung Cancer

Taiwan
Shengjing Hospital

Recruiting

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Breast Cancer | Immunotherapy | Stereotactic Radiotherapy

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Barmherzige Brüder Vienna

Completed

Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer

Bladder Cancer

Austria
Wuhan Union Hospital, China

Not yet recruiting

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma, PDAC

China
Fudan University

Recruiting

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Triple-Negative Breast Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Not yet recruiting

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

Biliary Tract Neoplasms
Chinese Society of Lung Cancer

Completed

Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung (C-TONG1002)

Carcinoma, Non-Small-Cell Lung

China
Zhejiang Cancer Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University

Completed

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients (nabPCESCC)

Esophageal Squamous Cell Carcinoma

China
Peng Liu

Not yet recruiting

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

Histological or Cytological Confirmed Stage Ⅲ and Ⅳa Thymoma

China
Mianyang Central Hospital

Unknown

Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus

Esophageal Squamous Cell Carcinoma
Chinese PLA General Hospital

Unknown

Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients

Cancer of Pancreas

China
Federal University of São Paulo
InCor Heart Institute; Hospital das Forças Armadas, Brazil

Completed

Intravenous High Dose NAC and Sodium Bicarbonate for the Prevention of Contrast-induced Acute Injury

Acute Renal Failure

Brazil
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Hunan Cancer... and other collaborators

Recruiting

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Asan Medical Center

Completed

Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma

Metastatic Biliary Cancer

Korea, Republic of
Zhejiang Cancer Hospital

Unknown

Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer

Biliary Tract Cancer

China
Wakayama Medical University

Unknown

Study of NAC of GA Therapy for Patients With BRPC

Pancreatic Ductal Adenocarcinoma

Japan
Fudan University
Fujian Cancer Hospital; Affiliated Hospital of Jiangnan University; First Affiliated... and other collaborators

Completed

A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma

Esophageal Squamous Cell Carcinoma

China
Qilu Hospital of Shandong University

Withdrawn

Neoadjuvant Immunotherapy to ESCC

Esophagus SCC

China
UNC Lineberger Comprehensive Cancer Center

Terminated

Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC (LCCC1407)

Stage IIIA Non-Small Cell Lung Cancer

United States
Catholic University of the Sacred Heart
Policlinico Casilino ASL RMB

Completed

Sodium Bicarbonate and N-Acetylcysteine for Nephroprotection in Acute Myocardial Infarction (BINARIO)

Acute Kidney Injury | Acute Myocardial Infarction

Italy
Asan Medical Center
Ulsan University Hospital; Bundang CHA Hospital

Completed

Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer

Pancreatic Cancer | Metastatic Pancreatic Cancer

Korea, Republic of
Samsung Medical Center

Unknown

Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression

Non-small Cell Lung Cancer

Korea, Republic of
The European Uro-Oncology Group
Centre for Human Drug Research, Netherlands

Recruiting

Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (URANUS)

Upper Tract Urothelial Carcinoma

Norway, Spain, Netherlands
Yonsei University

Unknown

Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

Korea, Republic of
Huazhong University of Science and Technology
CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

Biliary Tract Cancer

China
IRCCS San Raffaele

Completed

A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma (PACT-19)

Pancreatic Cancer

Italy
Genzyme, a Sanofi Company

Completed

Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC

Non Small Cell Lung Cancer
Nanjing Luye Sike Pharmaceutical Co., Ltd.

Unknown

Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer

Breast Cancer

China
HonorHealth Research Institute
Cantex Pharmaceuticals

Terminated

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

Metastatic Pancreatic Cancer

United States
Samsung Medical Center

Unknown

Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma (XP versus XT)

First Line Chemotherapy | Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel | Advanced or Recurrent Esophageal Squamous Cell Carcinoma

Korea, Republic of
Sun Yat-sen University

Unknown

GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma

Stage IV Nasopharyngeal Carcinoma

China
Tianjin Medical University Cancer Institute and...
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Unknown

Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC

Esophageal Cancer Stage III | Esophageal Cancer Stage IIB

China
Zhejiang University

Recruiting

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma by AJCC V8 Stage

China
AHS Cancer Control Alberta
Celgene

Active, not recruiting

A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC)

Unresectable Biliary Tract Cancer

Canada
University of Texas Southwestern Medical Center
BerGenBio ASA; Translational Genomics Research Institute; Triligent International

Terminated

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

Cancer of Pancreas

United States
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
OncoSec Medical Incorporated
Merck Sharp & Dohme LLC

Active, not recruiting

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Triple Negative Breast Cancer

United States, Australia
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Chinese PLA General Hospital

Completed

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

Carcinoma, Transitional Cell

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer AJCC v8 | Unresectable Extrahepatic... and other conditions

United States
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

Esophageal Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma

China

Search clinical trials for: Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations